|Bid||0.5600 x 0|
|Ask||0.5700 x 0|
|Day's Range||0.5600 - 0.6000|
|52 Week Range||0.4100 - 1.1200|
|Beta (5Y Monthly)||0.33|
|PE Ratio (TTM)||40.00|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Vancouver, British Columbia--(Newsfile Corp. - January 19, 2022) - Resverlogix Corp. (TSX: RVX) (OTC Pink: RVXCF), a world leader in epigenetics, or gene regulation, has begun enrollment and dosing of patients in a Phase 2b clinical trial at a site at the University of Alberta Hospital in Edmonton, to evaluate the safety and efficacy of apabetalone as a potential oral treatment for COVID-19.InvestmentPitch.com has produced a "video" which discusses this news. If this link ...
Resverlogix commences dosing of patients in Phase 2b COVID-19 study Patients have received their first dose of apabetalone CALGARY, Alberta, Jan. 18, 2022 (GLOBE NEWSWIRE) -- Resverlogix Corp. ("Resverlogix") (TSX:RVX) is pleased to announce today that enrollment and dosing of patients has commenced in a Phase 2b study at a site at the University of Alberta Hospital in Edmonton. The trial will evaluate the safety and efficacy of apabetalone as a potential oral treatment for COVID-19. Apabetalone
If you want to know who really controls Resverlogix Corp. ( TSE:RVX ), then you'll have to look at the makeup of its...